For the sixth consecutive year, New York-based Pfizer Inc.'s pharmaceutical sales organization placed first overall in Newtown, PA-based healthcare consulting firm Scott-Levin's survey of U.S. physicians in nine core specialty groups: general/family practitioners, internists, pediatricians, obstetrician/gynecologists, psychiatrists, general surgeons, gastroenterologists, cardiologists and otorhinolaryngologists.
For the sixth consecutive year, New York-based Pfizer Inc.'s pharmaceutical sales organization placed first overall in Newtown, PA-based healthcare consulting firm Scott-Levin's survey of U.S. physicians in nine core specialty groups: general/family practitioners, internists, pediatricians, obstetrician/gynecologists, psychiatrists, general surgeons, gastroenterologists, cardiologists and otorhinolaryngologists.
Pfizer was rated first by five of these key physician groups, as well as urologists, nephrologists, emergency medicine specialists and neurosurgeons. The company also was ranked number one by nurse practitioners and physician assistants.
The report also examined sales force value among physician specialty groups. The leading sales forces among select groups of specialists:
•Â Allergists: Aventis Pharmaceuticals, Parsippany, NJ.
•Â OB/GYNs: Wyeth-Ayerst Laboratories, Philadelphia, PA.
•Â Oncologists: Bristol-Myers Squibb Co., New York.
•Â Orthopedic surgeons: Merck & Co. Inc., Whitehouse Station, NJ.
•Â Psychiatrists: Eli Lilly and Co., Indianapolis.
These rankings come from "Pharmaceutical Sales Force Structures & Strategies 2000-2001," the 13th edition of Scott-Levin's annual study of pharmaceutical sales forces. Thirty-three physician specialty groups and other healthcare providers were surveyed for this year's report. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.